These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11364713)

  • 1. Update on nevirapine: quest for a niche.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Sep; 3(9):37-43. PubMed ID: 11364713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two studies suggest nevirapine benefit for children.
    AIDS Patient Care STDS; 1997 Jun; 11(3):195. PubMed ID: 11361798
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
    Conway B
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S130-4. PubMed ID: 10860897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
    Aguirrebengoa K; Mallolas J; Uriz J; Torres Tortosa M
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():3-9. PubMed ID: 9053024
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs for HIV infection.
    Med Lett Drugs Ther; 1997 Dec; 39(1015):111-6. PubMed ID: 9402928
    [No Abstract]   [Full Text] [Related]  

  • 8. Nevirapine: new preparation. In second-line triple-drug anti-HIV regimens.
    Prescrire Int; 1998 Oct; 7(37):140-1. PubMed ID: 10915417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV drug now approved for use with protease inhibitors.
    Nurse Pract; 1998 Oct; 23(10):89. PubMed ID: 9805335
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral load--how low is best?
    TreatmentUpdate; 1998 Dec; 10(10):2-3. PubMed ID: 11366016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV in the brain: an interview with Dr. Michael Wool, UCLA researcher.
    Wool M
    Posit Dir News; 1998 Jan; 10(1):18-24. PubMed ID: 11365052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV treatment options.
    Smith D
    AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV resistance: the new enemy.
    Colvin R
    Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral resistance: a major challenge in managing HIV disease.
    Boucher CA; Reedijk M
    J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014
    [No Abstract]   [Full Text] [Related]  

  • 18. Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
    Yamamoto Y; Yasuoka A; Yasuoka C; Genka I; Teruya K; Kikuchi Y; Tachikawa N; Oka S
    Jpn J Infect Dis; 2000 Dec; 53(6):244-5. PubMed ID: 11227023
    [No Abstract]   [Full Text] [Related]  

  • 19. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
    Ferrer E; Podzamczer D; Arnedo M; Fumero E; McKenna P; Rinehart A; Pérez JL; Barberá MJ; Pumarola T; Gatell JM; Gudiol F;
    J Infect Dis; 2003 Feb; 187(4):687-90. PubMed ID: 12599088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch study of nevirapine.
    AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.